BRIEF

on SphingoTec GmbH

SphingoTec Launches ELISA sphingotest® penKid® for Kidney Biomarker Research

SphingoTec GmbH has launched the ELISA sphingotest® penKid®, expanding kidney biomarker testing accessibility for research applications. This new assay allows the measurement of the kidney function biomarker Proenkephalin 119-159 (penKid) using standard laboratory equipment.

The introduction addresses increasing scientific interest in penKid as a marker of kidney function, especially in critical care. Unlike previous assays requiring specialized equipment, this ELISA version enables broader adoption in research labs globally.

Ensuring data consistency, the ELISA maintains excellent correlation with SphingoTec’s reference chemiluminescence assay, offering reliable results. Its robust design supports large-scale, high-throughput research, enhancing the exploration of kidney functions.

Through out-licensing and strategic partnerships, like with Boditech Med, SphingoTec combines clinical use and scientific exploration, reinforcing its commitment to advancing diagnostics in critical care.

R. H.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all SphingoTec GmbH news